Bioequivalence Study of Zidovudine 300 mg Tablets, USP Under Fasting Conditions
Status:
Completed
Trial end date:
2004-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative bioavailability of the test formulation
of Zidovudine 300 mg tablets with an already marketed reference formulation RETROVIR ® 300 mg
tablets (GlaxoSmithKline), under fasted conditions in healthy male and female adult subjects.